Publikace
- Syntéza a úvodní in vitro hodnocení nových aroylhydrazonových chelátorů železa se zvýšenou stabilitou proti plazmatické hydrolýze2011 | Farmaceutická fakulta v Hradci Králové
- Novel SPME fibers based on a plastic support for determination of plasma protein binding of thiosemicarbazone metal chelators: a case example of DpC, an anti-cancer drug that entered clinical trials2019 | Farmaceutická fakulta v Hradci Králové
- Pharmacokinetics of the cardioprotective drug dexrazoxane and its active metabolite ADR-925 with focus on cardiomyocytes and the heart2018 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents2015 | Farmaceutická fakulta v Hradci Králové, Lékařská fakulta v Hradci Králové
- In Vitro Characterization of the Pharmacological Properties of the Anti-Cancer Chelator, Bp4eT, and Its Phase I Metabolites2015 | Farmaceutická fakulta v Hradci Králové
- LC-UV/MS methods for the analysis of prochelator-Boronyl salicylaldehyde isonicotinoyl hydrazone (BSIH) and its active chelator salicylaldehyde isonicotinoyl hydrazone (SIH)2015 | Farmaceutická fakulta v Hradci Králové
- Simultaneous determination of the novel thiosemicarbazone anti-cancer agent, Bp4eT, and its main phase I metabolites in plasma: Application to a pilot pharmacokinetic study in rats2014 | Farmaceutická fakulta v Hradci Králové
- Identification of in vitro metabolites of the novel anti-tumor thiosemicarbazone, DpC, using ultra-high performance liquid chromatography-quadrupole-time-of-flight mass spectrometry2013 | Farmaceutická fakulta v Hradci Králové
- Development of LC-MS/MS method for the simultaneous analysis of the cardioprotective drug dexrazoxane and its metabolite ADR-925 in isolated cardiomyocytes and cell culture medium2013 | Farmaceutická fakulta v Hradci Králové
- LC-MS/MS identification of the principal in vitro and in vivo phase I metabolites of the novel thiosemicarbazone anti-cancer drug, Bp4eT2012 | Farmaceutická fakulta v Hradci Králové
Loading network view...